The Department of Health and Social Care (DHSC) will increase medicine reimbursement prices by £15 million in June in an attempt to minimise the ‘significant cash flow problems’ facing the sector, PSNC have announced.
This change comes amid growing pressure from the sector who have called on the government for more financial support for community pharmacy to help with economic issues brought about by Covid-19.
According to PSNC, the decision for the increase in category M reimbursement prices was made based on medicine margin data from last year as well as predictions for prices in 2020/21.
However, according to PSNC Chief Executive Simon Dukes, this financial aid is ‘not enough.’
‘All pharmacies are facing significant and wide-ranging financial issues as a result of the COVID-19 pandemic, and we are continuing to press for urgent additional investment in the sector.
‘The Committee of PSNC will meet later this week to review how we can continue to make the strongest case for the sector and also to consider what the ongoing challenges for pharmacies will be as we move out of full lockdown and into a new recovery phase of health service delivery.’
PSNC and DHSC will continue to look at the medicine margin data to identify when a further increase in funding is necessary.
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.